There are 2934 resources available
6572 - CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC)
Presenter: Thomas Yau
Session: Proffered Paper 1 – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
How to select patients for immunotherapy doublet
Presenter: Camillo Guglielmo Porta
Session: Frontline in mRCC: Ready to select treatment?
Resources:
Slides
Webcast
Prevention and treatment of cancer and cancer-treatment related nausea and vomiting
Presenter: Karin Jordan
Session: ESMO-MASCC Collaborative session: Management of cancer and anticancer therapy induced side effects
Resources:
Slides
Webcast
Biomarker in RCC: Clinical perspective
Presenter: Toni Choueiri
Session: Frontline in mRCC: Ready to select treatment?
Resources:
Slides
Webcast
Introduction
Presenter: Iain Hagan
Session: Innate immune system and anti-mitotic agents: Two fields getting together
Resources:
Slides
Webcast
When it takes more than one drug to survive: The myeloma experience
Presenter: Katheryn Elun Morgan
Session: Drugs in combination
Resources:
Slides
Webcast
TGFb and PD1: The relevance of tumour associated macrophages
Presenter: Thomas Powles
Session: Innate immune system and anti-mitotic agents: Two fields getting together
Resources:
Slides
Webcast
Cytoplasmic DNA and c-GAS STING signalling
Presenter: Joan Seoane
Session: Innate immune system and anti-mitotic agents: Two fields getting together
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Joan Seoane
Session: Innate immune system and anti-mitotic agents: Two fields getting together
Resources:
Slides
Webcast
Methodological principles and current technological advances
Presenter: Michael Speicher
Session: The clinical utility of analysing circulating tumor DNA in patients with colorectal cancer (CRC)
Resources:
Slides
Webcast